{
    "clinical_study": {
        "@rank": "78757", 
        "arm_group": [
            {
                "arm_group_label": "SOM230LAR 20mg", 
                "arm_group_type": "Experimental", 
                "description": "10 enrolled patients will be randomized to 20mg pasireotide LAR."
            }, 
            {
                "arm_group_label": "SOM230LAR 40mg", 
                "arm_group_type": "Experimental", 
                "description": "10 enrolled patients will be randomized to 40mg pasireotide LAR."
            }, 
            {
                "arm_group_label": "SOM230LAR 60mg", 
                "arm_group_type": "Experimental", 
                "description": "10 enrolled patients will be randomized to 60mg pasireotide LAR."
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate efficacy, safety, pharmacokinetics and pharmacodynamics of pasireotide LAR in\n      Japanese patients with active acromegaly or pituitary gigantism. Primary objective is to\n      assess the total-group efficacy of pasireotide LAR on the reduction of mean GH levels to <\n      2.5 \u00b5g/L and the normalization of IGF-1 at 3 months of study treatment."
        }, 
        "brief_title": "Efficacy and Safety of Pasireotide LAR in Japanese Patients With Acromegaly or Pituitary Gigantism", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Acromegaly, Pituitary Gigantism", 
        "condition_browse": {
            "mesh_term": [
                "Acromegaly", 
                "Gigantism"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with medication na\u00efve acromegaly or pituitary gigantism\n\n          -  Patients with inadequately controlled acromegaly or pituitary gigantism\n\n        Exclusion Criteria:\n\n          -  Diabetic patients whose blood glucose is poorly controlled as evidenced by HbA1c >8%\n\n          -  Patients who have congestive heart failure (NYHA Class III or IV), unstable angina,\n             sustained ventricular tachycardia, ventricular fibrillation, clinically significant\n             bradycardia, advanced heart block or a history of acute myocardial infarction within\n             the six months preceding enrollment\n\n          -  Patients with risk factors for torsade de pointes, i.e. patients with a baseline QTcF\n             > 470 ms, hypokalemia, hypomagnesemia, hypocalcemia, family history of long QT\n             syndrome, or patients receiving a concomitant medication known to prolong QT interval"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01673646", 
            "org_study_id": "CSOM230C1202"
        }, 
        "intervention": {
            "arm_group_label": [
                "SOM230LAR 20mg", 
                "SOM230LAR 40mg", 
                "SOM230LAR 60mg"
            ], 
            "description": "Intramuscular administration of pasireotide LAR will be repeated every month (1 month = 28 days) for 12 months in core phase. It is permitted to increase the dose up to 60 mg in a patient showing the following biochemical test results after 3 and 6 months of study treatment: mean GH levels \u22652.5 \u00b5g/L and/or IGF-1 > ULN. In the event of any problem with tolerability, it is permitted to reduce the next lower dosage level at any time.", 
            "intervention_name": "SOM230LAR", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "SOM230, Pasireotide, acromegaly, Phase II", 
        "lastchanged_date": "February 24, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Nagoya-city", 
                        "country": "Japan", 
                        "state": "Aichi", 
                        "zip": "466-8560"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toyoake", 
                        "country": "Japan", 
                        "state": "Aichi", 
                        "zip": "470-1192"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chiba-city", 
                        "country": "Japan", 
                        "state": "Chiba", 
                        "zip": "260-8677"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yoshida-gun", 
                        "country": "Japan", 
                        "state": "Fukui", 
                        "zip": "+8910-1193"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fukuoka-city", 
                        "country": "Japan", 
                        "state": "Fukuoka", 
                        "zip": "812-8582"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kitakyushu", 
                        "country": "Japan", 
                        "state": "Fukuoka", 
                        "zip": "807-8556"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fukushima-city", 
                        "country": "Japan", 
                        "state": "Fukushima", 
                        "zip": "960-1295"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Maebashi-city", 
                        "country": "Japan", 
                        "state": "Gunma", 
                        "zip": "371-8511"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sapporo-city", 
                        "country": "Japan", 
                        "state": "Hokkaido", 
                        "zip": "060-8648"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kobe-city", 
                        "country": "Japan", 
                        "state": "Hyogo", 
                        "zip": "650-0017"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Morioka-city", 
                        "country": "Japan", 
                        "state": "Iwate", 
                        "zip": "020-8505"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kita-gun", 
                        "country": "Japan", 
                        "state": "Kagawa", 
                        "zip": "761-0793"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kagoshima-city", 
                        "country": "Japan", 
                        "state": "Kagoshima", 
                        "zip": "890-8520"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Isehara-city", 
                        "country": "Japan", 
                        "state": "Kanagawa", 
                        "zip": "259-1193"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kawasaki", 
                        "country": "Japan", 
                        "state": "Kanagawa", 
                        "zip": "211-8510"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yokohama", 
                        "country": "Japan", 
                        "state": "Kanagawa", 
                        "zip": "222-0036"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yokohama", 
                        "country": "Japan", 
                        "state": "Kanagawa", 
                        "zip": "232-0024"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyoto-city", 
                        "country": "Japan", 
                        "state": "Kyoto", 
                        "zip": "612-8555"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sendai-city", 
                        "country": "Japan", 
                        "state": "Miyagi", 
                        "zip": "980-8574"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Okayama-city", 
                        "country": "Japan", 
                        "state": "Okayama", 
                        "zip": "700-8558"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Osaka-city", 
                        "country": "Japan", 
                        "state": "Osaka", 
                        "zip": "534-0021"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Suita-city", 
                        "country": "Japan", 
                        "state": "Osaka", 
                        "zip": "565-0871"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tokorozawa", 
                        "country": "Japan", 
                        "state": "Saitama", 
                        "zip": "359-8513"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamamatsu", 
                        "country": "Japan", 
                        "state": "Shizuoka", 
                        "zip": "431-3192"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bunkyo-ku", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "113-8603"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bunkyo-ku", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "113-8655"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Itabashi-ku", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "173-8610"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Minato-ku", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "105-8470"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ota-ku", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "143-8541"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shinjuku-ku", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "162-8666"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Osaka", 
                        "country": "Japan", 
                        "zip": "530-8480"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shizuoka", 
                        "country": "Japan", 
                        "zip": "420-8527"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yamagata", 
                        "country": "Japan", 
                        "zip": "990-9585"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Multicenter, Open-label, Randomized, Phase II Study to Evaluate Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Pasireotide LAR in Japanese Patients With Active Acromegaly or Pituitary Gigantism", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+81337978748"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Assess the total-group efficacy of pasireotide LAR on the reduction of mean GH levels to < 2.5 \u00b5g/L and the normalization of IGF-1 at 3 months of study treatment.", 
            "measure": "Growth Hormone (GH) and  glucagon-like peptide-1 (IGF-1)", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01673646"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Assess the effect of each starting dose pasireotide LAR on the reduction of mean GH levels to < 2.5 \u00b5g/L and the normalization of IGF-1 at 3 months of study treatment", 
                "measure": "GH and IGF-1", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Assess Ctrough, Cmax and accumulation ratio of pasireotide LAR 20 mg, 40 mg and 60 mg", 
                "measure": "Profile of Pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "predose, day2, day15, day22 and every 28days up to 12 months"
            }, 
            {
                "description": "Assess the tolerability and safety profile of pasireotide LAR at 3 months and during and after the 24- month study treatment using the National Cancer Institute-Common Toxicology Criteria (NCI-CTC) grading scale", 
                "measure": "Number of patients with Adverse Events as a Measure of safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "every 28days up to 24 months"
            }, 
            {
                "description": "Assess the effect of pasireotide LAR on the reduction of mean GH levels to < 2.5 \u00b5g/L at 3, 6, 9, 12, 18 and 24 months of study treatment and the change of mean GH level from baseline", 
                "measure": "GH", 
                "safety_issue": "No", 
                "time_frame": "Baeline, 3 months, 6 months, 9 months, 12 months, 18 months and 24 motnhs"
            }, 
            {
                "description": "Assess the effect of pasireotide LAR on the normalization of IGF-1 at 3, 6, 9, 12, 18, 24 months of study treatment", 
                "measure": "IGF-1", 
                "safety_issue": "No", 
                "time_frame": "3 months, 6 months, 9 months, 12 months, 18 months and 24 months"
            }, 
            {
                "description": "Assess the effect of pasireotide LAR on the change of tumor volume at 6and 12 months of study treatment", 
                "measure": "Tumor volume", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 6 months and 12 months"
            }, 
            {
                "description": "Clinical signs include ring size, headache, fatigue, perspiration, paresthesias, osteoarthralgia", 
                "measure": "Change of clinical signs from baseline", 
                "safety_issue": "No", 
                "time_frame": "Baseline, every 3months up to 12 months"
            }, 
            {
                "description": "Assess the effect of pasireotide LAR on the change of PRL level from baseline", 
                "measure": "Prolactin (PRL)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, every 3 months up to 12 months"
            }, 
            {
                "description": "Assess the relationship between pasireotide plasma concentration and GH/IGF-1", 
                "measure": "Profile of Pharmacokinetic/Pharmacodynamic", 
                "safety_issue": "No", 
                "time_frame": "Day1, Day2, Day15, Day22, every 28days up to 6 months"
            }, 
            {
                "description": "Assess the total-group efficacy of pasireotide LAR on the reduction of mean GH levels to < 2.5 \u00b5g/L and the normalization of IGF-1 at 6, 9, 12, 18, 24 months of study treatment.", 
                "measure": "GH and IGF-1", 
                "safety_issue": "No", 
                "time_frame": "6months, 9 months, 12 months 18 months and 12 months"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}